Is the business good?
How good a business is LQDA?
Liquidia Corporation keeps 37% of every revenue dollar as operating profit, against 12% for the median Drug Manufacturers - Specialty & Generic name.
37%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q2 2026
- Cash conversion
- 1.09×
Cash conversion · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- +18%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 12%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −7989% |
| FY2021 | −263% |
| FY2022 | −243% |
| FY2023 | −420% |
| FY2024 | −867% |
| FY2025 | −32% |
Details›
- Operating margin12 months to Q2 2026
- 37%
- Net margin12 months to Q2 2026
- 31%
- Free cash flow margin
- 33%
- R&D as % of revenue
- 12%
- Revenue, trailing twelve months
- $451M
- Free cash flow, trailing twelve months
- $151M
- Net income, trailing twelve months
- $139M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #17 of 28 by Smart Score